In last trading session, Cardiff Oncology Inc (NASDAQ:CRDF) saw 1.55 million shares changing hands with its beta currently measuring 1.55. Company’s recent per share price level of $3.1 trading at -$0.1 or -3.13% at ring of the bell on the day assigns it a market valuation of $206.23M. That closing price of CRDF’s stock is at a discount of -81.94% from its 52-week high price of $5.64 and is indicating a premium of 35.16% from its 52-week low price of $2.01.
For Cardiff Oncology Inc (CRDF), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Upright in the red during last session for losing -3.13%, in the last five days CRDF remained trading in the red while hitting it’s week-highest on Wednesday, 06/18/25 when the stock touched $3.1 price level, adding 9.88% to its value on the day. Cardiff Oncology Inc’s shares saw a change of 26.53% in year-to-date performance and have moved -16.22% in past 5-day. Cardiff Oncology Inc (NASDAQ:CRDF) showed a performance of 2.31% in past 30-days.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 19.36% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 15.19% while estimates for its earnings growth in next 5 years are of -7.49%.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
BLACKROCK INC. is the top institutional holder at CRDF for having 2.63 million shares of worth $5.84 million. And as of 2024-06-30, it was holding 5.8637 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 2.14 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.766 of outstanding shares, having a total worth of $4.74 million.
